Literature DB >> 11901832

Genetic strategies for the personalization of antipsychotic treatment.

R W Kerwin1, D T Mancama, M J Arranz.   

Abstract

Pharmacogenetic research into complex traits, such as response to antipsychotic treatment has proved a difficult task. Nevertheless, investigation of drug metabolic enzymes has revealed polymorphisms in specific cytochrome P450 genes responsible for treatment-induced toxic reactions. However, the picture becomes more complicated when drug target sites are investigated in search of genetic influence. Most antipsychotic drugs are multitarget, denoting a complex mechanism of action. Although individual genes have been reported to influence antipsychotic response, no single gene can account for the variability observed in treatment response. Current investigations focus on single gene variants that may be associated with particular side effects or symptoms as well as contributing to general response. The scope of this article is to review recent advances of pharmacogenetic research on antipsychotic drugs and the strategies under development for the individualization of treatment.

Mesh:

Substances:

Year:  2001        PMID: 11901832     DOI: 10.1586/14737159.1.3.275

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  1 in total

1.  Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.

Authors:  David Villagra; John Goethe; Harold I Schwartz; Bonnie Szarek; Mohan Kocherla; Krystyna Gorowski; Andreas Windemuth; Gualberto Ruaño
Journal:  Biomark Med       Date:  2011-08       Impact factor: 2.851

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.